News|Articles|June 11, 2026

ADA 2026 Recap: 5 Key Presentations to Know

Catch up on any data and key clinician perspectives presented at the American Diabetes Association Scientific Sessions 2026.

The American Diabetes Association (ADA) Scientific Sessions 2026, in New Orleans, Louisiana, gathered together some of the greatest minds in endocrinology to discuss the latest major clinical trials and technological advancements in diabetes and obesity care. From Eli Lilly’s triple receptor agonist retatrutide to the ultra-long-acting GLP-1 receptor agonist berobenatide made by Pfizer, this year’s meeting was dominated by major steps forward in incretin-based therapies.

Related to this article

October 23rd, 2026

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

October 22nd, 2026

AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women

Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.

October 24th, 2026

Kidney Compass: New FIND-CKD Finerenone Data From ASN Kidney Week 2026

Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.

October 24th, 2026

Kidney Compass: Final 2-Year TELIGAN Data for Telitacicept in IgA Nephropathy

Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.

October 24th, 2026

Sparsentan Lowers Inflammatory, Complement Biomarkers in IgAN

A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.

October 23rd, 2026

Tenapanor Lowers Serum Phosphate Regardless of Binder Use in Dialysis

Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.

October 23rd, 2026

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.

October 23rd, 2026

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.